CORMEDIX INC. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
CORMEDIX INC. (CRMD) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $6.50 million as of 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2023-11-14
- 2023-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $6.50M.
- 2021-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $5.52M.
- 2021-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $7.54M.
- 2021-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $8.59M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2023-09-30 | $6.50M 10-Q · filed 2023-11-14 |
| 2021-12-31 | $5.52M 10-K · filed 2022-03-29 |
| 2021-09-30 | $7.54M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $8.59M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $8.08M 10-Q · filed 2021-05-13 |
| 2020-09-30 | $3.72M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $3.88M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $2.83M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.86M 10-K · filed 2020-03-16 |
| 2019-09-30 | $2.77M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $2.52M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $2.45M 10-Q · filed 2019-05-13 |
| 2018-09-30 | $1.95M 10-Q · filed 2018-11-14 |
| 2018-06-30 | $2.27M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $2.61M 10-Q · filed 2018-05-15 |
| 2017-09-30 | $3.18M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $3.96M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $4.46M 10-Q · filed 2017-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |